Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 312.50 | 200.50 | 318.00 | 286.50 | 1.1099 | 1.4491 |
| SK-BR-3 | Erlotinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 388.00 | 286.50 | 1.3543 | 2.6042 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 251.00 | 286.50 | 0.8761 | 0.5469 |
| SK-BR-3 | 17-AAG | 0.0001 | uM | 9 | 312.50 | 200.50 | 406.00 | 286.50 | 1.4171 | 2.9360 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 256.00 | 286.50 | 0.8935 | 0.6073 | |
| SK-BR-3 | 17-AAG | 0.000302 | uM | 9 | 312.50 | 200.50 | 334.00 | 286.50 | 1.1658 | 1.6941 |
| SK-BR-3 | Erlotinib | 10 | uM | 9 | 312.50 | 200.50 | 191.00 | 286.50 | 0.6667 | -0.0900 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 312.50 | 200.50 | 428.00 | 286.50 | 1.4939 | 3.3607 |
| SK-BR-3 | Lapatinib | 10 | uM | 9 | 312.50 | 200.50 | 100.00 | 286.50 | 0.3490 | -0.7410 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 443.00 | 286.50 | 1.5462 | 3.6624 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 376.00 | 286.50 | 1.3124 | 2.3909 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 312.50 | 200.50 | 336.00 | 286.50 | 1.1728 | 1.7255 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 218.00 | 286.50 | 0.7609 | 0.1765 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 230.00 | 286.50 | 0.8028 | 0.3055 | |
| SK-BR-3 | Erlotinib | 0.01 | uM | 9 | 312.50 | 200.50 | 402.00 | 286.50 | 1.4031 | 2.8610 |
| SK-BR-3 | Erlotinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 271.00 | 286.50 | 0.9459 | 0.7952 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 312.50 | 200.50 | 128.00 | 286.50 | 0.4468 | -0.5817 |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 312.00 | 286.50 | 1.0890 | 1.3602 |
| SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 312.50 | 200.50 | 346.00 | 286.50 | 1.2077 | 1.8852 |
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 312.50 | 200.50 | 280.00 | 286.50 | 0.9773 | 0.9128 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 312.50 | 200.50 | 325.00 | 286.50 | 1.1344 | 1.5549 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 312.50 | 200.50 | 165.00 | 286.50 | 0.5759 | -0.3151 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 9 | 312.50 | 200.50 | 194.00 | 286.50 | 0.6771 | -0.0620 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 419.00 | 286.50 | 1.4625 | 3.1844 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 312.50 | 200.50 | 353.00 | 286.50 | 1.2321 | 1.9997 |